Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and GSK2141795 in AML with RAS Mutations
NCT01907815Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib, uprosertib in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Oct 2013; status: terminated.
02
Drugs
trametinibuprosertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01907815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01907815.